Proscia Earns Top Score in KLAS Digital Pathology Report

Why It Matters

The rating validates Proscia’s market leadership and signals strong demand for interoperable, high‑performing pathology software, influencing purchasing decisions across hospitals and labs.

Key Takeaways

• Proscia scored 95.2, highest U.S. digital pathology rating
• A+ grades across six customer experience dimensions
• All customers view Concentriq as long‑term solution
• Concentriq integrates with 15+ LIS, including Epic Beaker
• Also named Best in KLAS Europe 2026

Pulse Analysis

The KLAS Research report is a benchmark that many healthcare providers trust when evaluating technology partners. Proscia’s 95.2 score not only places it at the top of the U.S. digital pathology market but also reflects a broad consensus among end‑users that its platform delivers superior performance, reliability, and support. Such independent validation often accelerates adoption cycles, as hospital CIOs and lab directors lean on peer‑driven data to justify multi‑year investments.

A key differentiator for Proscia is the Concentriq platform’s extensive integration capability. By connecting with over 15 laboratory information systems—including the widely used Epic Beaker—Concentriq reduces data silos and streamlines workflow automation. This interoperability translates into faster turnaround times for diagnostic results, lower operational costs, and enhanced compliance with regulatory standards. Laboratories that prioritize seamless data exchange view these features as essential for scaling digital pathology initiatives.

The dual recognition—U.S. top score and Global Best in KLAS Europe—strengthens Proscia’s competitive positioning against incumbents such as Philips and Leica. It also underscores a broader industry shift toward cloud‑native, AI‑enabled pathology solutions that can adapt to evolving clinical demands. Investors and analysts are likely to view these accolades as a catalyst for revenue growth, while vendors may intensify R&D to match Proscia’s integration breadth. In a market projected to exceed $5 billion by 2028, Proscia’s momentum suggests it will play a pivotal role in shaping the next generation of diagnostic workflows.